Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SYS6020 in Refractory Active Systemic Lupus Erythematosus
NCT06694298Phase 1Not yet recruiting
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Dec 2024
- Primary completion
- Jan 2029
- Modality
- Small Interfering RNA (siRNA), CAR-T Cells, Antisense DNA
01
Overview
Phase 1, open-label, single-arm trial of SYS6020 in systemic lupus erythematosus (SLE), sponsored by CSPC ZhongQi Pharmaceutical Technology. Primary endpoints: Dose Limiting Toxicity at 28 days, Incidence of adverse events and serious adverse events at 28 days and 2 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
SYS6020
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06694298.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06694298.